Clinical Trials Logo

Carcinoma, Merkel Cell clinical trials

View clinical trials related to Carcinoma, Merkel Cell.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04916002 Suspended - Clinical trials for Non-Small Cell Lung Cancer

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Start date: November 30, 2021
Phase: Phase 2
Study type: Interventional

The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: - How many participants' cancers respond to vidutolimod together with cemiplimab? - Is vidutolimod together with cemiplimab safe and well-tolerated? - How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.

NCT ID: NCT03712605 Suspended - Clinical trials for Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Start date: November 15, 2018
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.